Updates are available Correction dated 2024-02-21
Click to view Correction: https://doi.org/10.1038/s41388-024-02965-x
-
Authors
Peng, Haiyong http://orcid.org/0000-0003-0312-1337
Nerreter, Thomas
Mestermann, Katrin http://orcid.org/0000-0002-3585-5055
Wachter, Jakob
Chang, Jing http://orcid.org/0000-0002-8973-6377
Hudecek, Michael
Rader, Christoph http://orcid.org/0000-0001-9955-3454
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA174844, R01 CA181258, R01 CA204484, R21 CA229961, R21 CA263240)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Klorfine Foundation
- License Information
-
More Information
Article History
Received: 10 January 2022
Revised: 7 July 2022
Accepted: 8 July 2022
First Online: 20 July 2022
Change Date: 21 February 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41388-024-02965-x
Competing interests
: CR and HP are named inventors on a licensed patent family (assignee, University of Florida and Boehringer Ingelheim) that claims a set of anti-ROR1 mAbs used in this study including 324 (United States Patent 10,618,959). CR is named inventor on a licensed patent family (assignee, United States of America) that claims another set of anti-ROR1 mAbs used in this study including R12 (United States Patent 9,758,586).
